0001213900-21-020392 | 20-F | XBRL Viewer

115

Balance (in Shares) at Dec. 31, 2018

(1,909)

Balance at Dec. 31, 2018

$ 58

11,596

(18,038)

(6,384)

21,924,208

Issuance of ordinary shares and warrants, net of issuance costs

$ 16

14,022

14,038

Issuance of ordinary shares and warrants, net of issuance costs (in Shares)

4,762,656

Issuance of ordinary shares to employees and non-employees upon exercise of warrants

$ 1

136

137

Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)

454,166

Issuance of ordinary shares to investors upon exercise of warrants

^[1]

Issuance of ordinary shares to investors upon exercise of warrants (in Shares)

9,050

Additional consideration with respect to an assets purchase agreement, see note 1c and note 6

16,245

(10,276)

Balance (in Shares) at Dec. 31, 2019

(22,563)

Balance at Dec. 31, 2019

$ 75

31,748

(40,601)

(8,778)

27,150,080

Issuance of ordinary shares and warrants, net of issuance costs

$ 14

70,999

71,013

Issuance of ordinary shares and warrants, net of issuance costs (in Shares)

4,624,500

Initial public offering of ordinary shares, net of offering costs

$ 31

169,136

169,167

Initial public offering of ordinary shares, net of offering costs (in Shares)

10,555,556

Issuance of ordinary shares to employees and non-employees upon exercise of warrants

$ 3

497

500

Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)

997,863

Issuance of ordinary shares to investors upon exercise of warrants

$ 5

125

130

Issuance of ordinary shares to investors upon exercise of warrants (in Shares)

1,662,929

Conversion of related party liability to shareholders’ equity, see note 8a

24,781

$ 3

17,745

17,748

Conversion of related party liability to shareholders’ equity, see note 8a (in Shares)

1,109,245

Balance (in Shares) at Dec. 31, 2020

(43,815)

Balance at Dec. 31, 2020

$ 131

$ 315,031

$ (84,416)

$ 230,746

46,100,173

[1]	Less than 1 thousand US dollars.

Consolidated Statements of Cash Flows - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

CASH FLOWS FROM OPERATING ACTIVITIES:

Adjustments required to reconcile net loss to net cash used in operating activities:

$ (43,815)

$ (22,563)

$ (1,909)

Changes in operating assets and liabilities:

24,781

16,245

115

Depreciation

208

Prepaid expenses and other current assets

(4,478)

(1,564)

Related party prepaid expenses

1,081

(1,844)

Other non-current assets

(522)

(139)

Accounts payable

(103)

393

(134)

Operating lease

^[1]

Accrued expenses and other liabilities

2,359

970

Net cash used in operating activities

(21,487)

(5,524)

(3,671)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment

(13,937)

(125)

(73)

Net cash used in investing activities

(13,937)

(125)

(73)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of ordinary shares and warrants, net of issuance costs

71,013

14,038

3,684

Proceeds from initial public offering of ordinary shares, net of issuance costs

169,348

Proceeds from issuance of ordinary shares upon exercise of warrants

630

162

Deferred offering costs

(339)

Net cash provided by financing activities

240,991

13,861

3,684

NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

205,567

8,212

(60)

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR

8,217

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR

213,784

8,217

SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS:

Unpaid offering costs

858

issuance of ordinary shares to investor upon exercise of warrants

200

Operating lease liabilities arising from obtaining operating right-of-use assets

1,085

548

Additional consideration with respect to an assets purchase purchase agreement, see note 1c

(10,276)

Conversion of related party liability to shareholders’ equity

$ 17,748

[1]	Less than 1 thousand US dollars.

General

12 Months Ended

Dec. 31, 2020

Organization Consolidation and Presentation of Financial Statements [Abstract]

GENERAL:

NOTE 1 - GENERAL:

Nano-X Imaging Ltd, an Israeli Company (hereinafter “the Company” or “Nanox IL” or “the Successor Company”), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019.

On September 19, 2019, Nanox IL established Nanox Imaging Inc. (hereinafter “Nanox Inc.”), a wholly owned subsidiary in Japan.

On September 25, 2020, Nanox IL established Nano-X Korea Inc. (hereinafter “Nanox Korea”), a wholly owned subsidiary in Korea.

In August 2020, the Company completed an initial public offering (“IPO”) on the Nasdaq Global Select Market (the “Nasdaq”), in which it issued 9,178,744 ordinary shares, at a price per share of $18. During August 2020 the underwriters exercised their over-allotment option and purchased an additional 1,376,812 ordinary shares at the same price per share. The proceeds received from the IPO were $190 million (the net proceeds were approximately $169 million after deducting underwriting commissions and other offering expenses).

Nanox Imaging PLC is a public limited company incorporated in Gibraltar in 2012 (hereinafter “Nanox PLC” or “the predecessor company”). Nanox PLC developed certain technological capabilities aimed to design and build various applications for x-ray based imaging. Nanox PLC has been a development-stage company since its inception. Nanox PLC has a wholly owned subsidiary, Nanox Japan Inc. (hereinafter “Nanox Japan”). Nanox Japan primarily provided research and development services to Nanox PLC.

On September 3, 2019 (hereinafter “Transaction Date”), Nanox IL signed an Assets Purchase Agreement which was later amended on December 3, 2019 and December 31, 2019 (hereinafter “the APA”) with Nanox PLC.

Under the terms of the APA, Nanox IL purchased from Nanox PLC patents, patent applications and all other intellectual property rights, as well as all cash of Nanox PLC (less an amount of $200 thousand), with an exclusion of certain assets as defined in the APA (hereinafter “Acquired Assets”).

Under the terms of the APA, Nanox IL shall pay Nanox PLC $6.127 million as consideration for the purchase of the Acquired Assets, which reflects the fair value of the Acquired Assets (excluding cash) plus the cash balance as of the date of the APA, less $200 thousand. The purchase price shall be due and payable upon the closing of one of the following events: (a) an M&A event of Nanox IL, (b) an IPO of Nanox IL, or (c) a qualified equity financing of Nanox IL at a minimum company pre-money valuation of $100 million, with proceeds totaling at least $30 million.

In the event of an IPO or a qualified equity financing, Nanox IL has the option to pay for the Acquired Assets in cash or by the issuance of Nanox IL shares of the same series to be issued upon such event, in an amount reflecting a 25% discount on the per share price to be determined in such IPO or qualified equity financing. If Nanox IL chooses to pay for the Acquired Assets in cash in any of the events described above, then Nanox PLC has the right, at its sole discretion and in good faith, to reject such payment in cash, and require Nanox IL to pay for the Acquired Assets by the issuance of securities of the same series to be issued upon such equity financing events, in such amount which shall reflect a 25% discount on the per share price to be determined in such equity financing events.

In November 2019, Nanox PLC transferred to Nanox IL an amount of $7.2 million, which reflects the cash consideration under the APA. The total consideration of the purchase of the Acquired Assets is $13.3 million. The outstanding balance of $17.8 million reflects the related party liability of the expected future payment using the Company’s shares, refer to note 6.

In return to the Acquired Assets, the Company issued to Nanox PLC 1,109,245 ordinary shares during January 2020. See also note 6.

As of September, 3 2019, Nanox IL and Nanox PLC had the same shareholders and, therefore, the transaction was treated as a transaction under common control for accounting purposes.

The financial statements of the Company prior to the Transaction Date are the historical financial statements of Nanox PLC, which have been adjusted to reflect the fact that:

only the net assets that were transferred in the transaction according to the APA. Net assets which were not transferred in the transaction are not reflected in these consolidated financial statements.

no interests of Nanox Japan were transferred under the APA. The consolidated statements of operation include the costs incurred for services provided by Nanox Japan to Nanox PLC.

the consideration in the transaction (the “Related Party Liability”) was recorded at the beginning of the earliest period presented against a decrease in shareholders’ equity.

all of the share-related information reflects the share information of Nanox IL.

The Company’s solution, referred to as the Nanox System, has two integrated components – “Nanox.ARC” and “Nanox. CLOUD”. Nanox.ARC is a medical imaging system incorporating the Company’s novel digital X-ray source. Nanox. CLOUD is a cloud-based system designed to provide end-to-end medical imaging services, including services such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive AI systems, billing and reporting.

In January 2020, the Company submitted a 510(k) application for the Nanox Cart X-Ray System, which is a single-source version of the Nanox.ARC (the “Nanox Cart X-Ray System”) to an accredited Review Organization under the FDA’s 510(k) third party review program. During 2020 and the first quarter of 2021, the Company received additional information requests and submitted its official responses. On April 1, 2021, the Company received clearance from the FDA to market the Company's Nanox Cart X-Ray System. The Company plans to submit an additional 510(k) premarket notification to the FDA with respect to the multi-source Nanox.ARC and the Nanox.CLOUD during 2021.

The Company has experienced net losses and negative cash flows from operations since its inception. The Company anticipates such losses will continue until its product candidates reach commercial profitability. In August 2020, the Company completed an IPO on Nasdaq with net proceeds received from the IPO of approximately $169 million .Based on the Company’s financing activities during the year ended December 31, 2020, the Company has sufficient funds for its plans for the next twelve months from the issuance of these financial statements.

Current Impact of COVID-19

Following the December 2019 outbreak of Coronavirus (COVID-19) in China, it has spread into most countries across the world, including Israel, Japan and all 50 states within the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The COVID-19 pandemic has adversely impacted the Company’s operations in various ways. For example, the Company’s engineers are unable to make work-related trips to Korea or Israel to test and optimize the Nanox.ARC or to begin development of x-ray chip manufacturing in Korea. The potential business partners are unable to make on-site visits to the Company’s facilities or attend industry conferences and meetings to experience the Nanox.ARC, which has negatively impacted the Company’s business development and deployment activities. The external labs the Company works with have also been affected by COVID-19, resulting in delays in the Company’s timelines for obtaining regulatory approval. COVID-19 has also caused shutdowns or disruptions of business for our manufactures and suppliers. The continued spread of COVID-19 globally could adversely impact the Company’s development, manufacture or deployment of the Nanox Systems, which could adversely affect the Company’s ability to obtain regulatory approval for and to commercialize the Nanox Systems, increase the operating expenses and have a material adverse effect on the Company’s financial results. (For the process with the FDA, see note 1d above).

Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (hereinafter -“U.S GAAP”). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

Use of estimates in the preparation of financial statements

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company’s consolidated financial statements. As applicable to these consolidated financial statements, the most significant estimates relate to fair value of share-based payments.

Functional currency

The U.S. dollar is the currency of the primary economic environment in which the operations of the Company and its subsidiary is conducted. A substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar (“primary currency”).

Foreign currency assets and liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation process. Expense accounts are translated using the weighted average exchange rate during the period. Currency transaction gains and losses are presented in financial income and expenses, net.

Cash and cash equivalents

The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

Restricted Cash

As of December 31, 2020, the Company’s restricted cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit is presented at cost including accrued interest. This bank deposits is used as security for credit card use and collateralizing the Company’s lease contracts.

Property and equipment, net

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives:

	%
Computers and electronic equipment	10-33
Office furniture and lab equipment	6-20
Machines	10-20
Leasehold Improvement		10
Land		N/A

The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.

Impairment of long-lived assets

The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.

As of December 31, 2020, 2019 and 2018, the Company did not recognize an impairment loss on its long-lived assets.

Severance pay

Israeli labor law generally requires severance pay be granted upon dismissal of an employee or upon termination of employment under certain other circumstances. Pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), all of the Company’s employees in Israel are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments under Section 14 relieve the Company from any future severance payment obligation with respect to those employees and, as such, the Company may only utilize the insurance policies for the purpose of disbursement of severance pay. As a result, the Company does not recognize an asset nor liability for these employees.

In 2020, all of the Company’s employees in Israel are subject to Section 14.

Legal and other contingencies

Certain conditions, such as legal proceedings, may exist as of the date the consolidated financial statements are issued that may result in a loss to the Company, but that will only be resolved when one or more future events occur or fail to occur. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates with its legal advisors the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Such assessment inherently involves an exercise of judgment. Legal fees are expensed as incurred.

Management applies the guidance in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss would be incurred and the amount of the liability can be estimated, then the Company records an accrued expense in the Company’s consolidated financial statements based on its best estimate. Loss contingencies considered to be remote by management are generally not disclosed unless material. In September 2020, securities class action complaints were filed in the United States by certain of the Company’s shareholders against the Company and certain of the Company’s current officers and directors. For additional information see note 7.

Research and development expenses

Research and development expenses are charged to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.

Income tax

The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.

Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not been taken into account in computing the deferred income taxes, as it is the Company’s intent and ability to hold these investments.

The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).

Share-based compensation

The Company accounts for share-based compensation under ASC 718, “Compensation - Stock Compensation,” which requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to non-employees, employees, officers and directors.

ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing model as part of such estimation.

Prior to the adoption of ASU 2018-07, warrants issued to consultants and other non-employees, as compensation for services provided to the Company, were accounted for based upon the fair value of the warrants. The fair value of the warrants granted was measured on a final basis at the end of the related service period and was recognized over the related service period using the straight-line method. After the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of the grant. The compensation expense for non-employees is recognized without changes in the fair value of the award, over the requisite service period, which is the vesting period of the respective award using the straight line. The Company adopted ASU 2018-07 as of January 1, 2019 with no impact on its consolidated financial statements as all of the Company’s awards were fully vested at the adoption date.

Loss per share

Basic earnings per share is computed by dividing net income (loss) attributable to holders of ordinary shares of the Company by the weighted average number of ordinary shares outstanding for each reporting period.

In computing the Company’s diluted earnings per share, the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding include the dilutive effect of in-the-money options using the treasury stock method.

The Company did not take into account any dilutive instruments, such as investor warrants and share-based payments, since their effect, on a fully diluted basis, is anti-dilutive.

Fair value measurement

Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

	Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

	Level 2:	Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

	Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

The Company’s financial instruments consist mainly of cash and cash equivalents, restricted cash accounts payable, accrued expenses and other liabilities. The fair value of these financial instruments approximates their carrying values.

Concentration of Credit Risks

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash.

The Company’s cash and cash equivalents and restricted cash are invested with major banks in Israel, Korea and Japan. Generally, these investments may be redeemed upon demand and the Company believes that the financial institutions that hold the Company’s cash balances are financially sound and, accordingly, bear minimal risk.

Offering Costs

Deferred offering costs directly relating to the Company’s private and initial public offering, were capitalized and offset against proceeds upon the consummation of the private and IPO transactions in shareholders’ equity.

Leases

On January 1, 2019 the Company adopted ASU No. 2016-02, Leases (Topic 842), The Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use (“ROU”) assets, current maturities of operating leases and Non-current operating leases in the consolidated balance sheets.

The Company also elected not separating lease components from non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of operations on a straight-line basis over the lease term.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over the lease term. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined. As the Company’s leases do not provide an implicit rate, the Company’s uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term (see also note 5).

Newly issued and recently adopted accounting pronouncements:

Accounting Pronouncements Adopted in Current year

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments (“the Standard”). This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. ASU 2018-19 clarifies that receivables from operating leases are accounted for using the lease guidance and not as financial instruments. Since the Company has no financial instruments the Standard does not impact the Company’s consolidated financial statements.

Property and Equipment, Net

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT, NET

NOTE 3 - PROPERTY AND EQUIPMENT, NET:

Composition of property and equipment grouped by major classifications is as follows:

	December 31,
	2020			2019
	(U.S. Dollars in thousands)

Office furniture and lab equipment		820			325
Computers and electronic equipment		151			39
Machinery		1,762			-
Leasehold improvement		16			-
Land – See b below		6,297			-
Prepayments on account of production line in construction - See b below		5,318			-
		14,364			364
Less: accumulated depreciation		(344	)		(136	)
Total property and equipment, net		14,020			228

	a.	Total depreciation in respect of property and equipment were approximately $208 thousand, $53 thousand and $35 thousand for the years ended December 31, 2020, 2019 and 2018, respectively.

	b.	In December 2020, Nanox Korea purchased a land for approximately $6.2 million upon which it intends to build a manufacturing facility. Nanox Korea also rented a temporary fabrication plant and is in the process of preparing for the commencement of full manufacturing activities, including purchasing certain equipment and transferring certain technology.

Cash, Cash Equivalents and Restricted Cash

12 Months Ended

Dec. 31, 2020

Cash Equivalents And Restricted Cash [Abstract]

CASH, CASH EQUIVALENTS AND RESTRICTED CASH

NOTE 4 - CASH, CASH EQUIVALENTS AND RESTRICTED CASH:

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheet that sum to the same total amount as shown in the consolidated statement of cash flows.

	December 31,
	2020		2019
	(U.S. Dollars in thousands)
Cash and cash equivalents		213,468		8,072
Restricted bank deposit		316		145
Total cash, cash equivalents and restricted cash shown in the statement of cash flows		213,784		8,217

Leases

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

LEASES

NOTE 5 - LEASES:

As of December 31, 2020, the Company has four operating lease agreements for its car and facilities, as follows:

During the fourth quarter of 2019, the Company entered into an office lease agreement. This agreement is through December 31, 2021 with an option by the Company to extend the period for an additional 24 months. The monthly rent payment is approximately $13 thousand.

During June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023. The monthly rent payment for this agreement is approximately $15 thousand.

During November 2020, following the increase of the Company’s employees, the Company signed an additional lease agreement, for a leasing of another office complex through June 30, 2023. The monthly rent payment for this agreement is approximately $12 thousand.

During November 2020, the Company engaged with car lease company, for leasing of 6 vehicles. This agreement is effective through June 30, 2023 and the monthly payment for this agreement is approximately $6.5 thousand.

The table below presents the effects on the amounts relating to the Company’s total lease costs:

	Year ended December 31,		Year ended December 31,
	2020		2019
	(U.S. Dollars in thousands)		(U.S. Dollars In thousands)
Operating lease cost:
Fixed payments		276		25
Short-term lease cost		65		112
Total operating lease cost		341		137

The table below presents supplemental cash flow information related to operating leases:

	Year ended December 31,		Year ended December 31,
	2020		2019
	(U.S. Dollars in thousands)		(U.S. Dollars in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		169		25

Right-of-use assets obtained in exchange for lease obligations (non-cash):
Operating leases		1,085		548

The table below presents supplemental balance sheet information related to operating leases:

	December 31,			December 31,
	2020			2019
	(U.S. Dollars in thousands)			(U.S. Dollars in thousands)
Operating leases:
Operating lease right-of-use assets		1,359			526

Current maturities of operating leases		519			140
Non-current operating leases		923			386
Total operating lease liabilities		1,442			526

		December 31,			December 31,
		2020			2019
Weighted average remaining lease term
Operating leases		2.67			3.96

Weighted average discount rate
Operating leases		5.83	%		5.6	%

The table below presents maturities of operating lease liabilities:

	December 31,
	2020
	(U.S. Dollars in thousands)

2020		-
2021		588
2022		588
2023		382
2024 and thereafter		-
Total operating lease payments		1,558
Less: imputed interest		116
Present value of lease liabilities		1,442

Related Party Liability

12 Months Ended

Dec. 31, 2020

Related Party Liability [Abstract]

RELATED PARTY LIABILITY

NOTE 6 - RELATED PARTY LIABILITY

According to ASC 480, “Distinguishing Liabilities From Equity,” a financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on a fixed monetary amount known at inception. These liabilities are measured subsequently at fair value with changes in fair value recognized in earnings.

The Company analyzed the instrument’s provisions and concluded that it meets the above ASC 480 criteria and therefore accounted the expected future payment under the APA in accordance with ASC 480.

As of December 31, 2019, the Company recorded a Related Party Liability in an amount of $17.8 million, which represents the fair value of the shares that have been issued to Nanox PLC, based on the last financing round of the Company.

During January 2020, subject to entering into a share purchase agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Nanox IL’s Board approved the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled into equity.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 7 - COMMITMENTS AND CONTINGENCIES:

	a.	In September 2020, securities class action complaints were filed in the United States by certain of the Company’s shareholders against the Company and certain of the Company’s current officers and directors alleging violations of securities laws and seeking unspecified damages. On December 7, 2020, the proposed lead plaintiffs’ submissions were fully briefed. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. As of the date of issuance of these financial statements, the Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases.

	b.	For services with SixAI Ltd. (“SixAI”), see Note 10d.

Shareholders' Equity

12 Months Ended

Dec. 31, 2020

Stockholders' Equity Note [Abstract]

SHAREHOLDERS’ EQUITY

NOTE 8 - SHAREHOLDERS’ EQUITY:

Share capital

Each holder of the Company’s ordinary shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, and declared by the Company’s Board of Directors (the “Board”). Since inception, the Company has not declared any dividends.

Issuance of Equity

Ordinary Share issuances prior to the APA

During the year ended December 31, 2018, Nanox PLC entered into several agreements with third party investors, pursuant to which it raised an aggregate amount of $3,684 thousand at a purchase price of $2.21 per share.

On June 17, 2019, Nanox PLC issued 2,262,443 ordinary shares to third party investors for an aggregate purchase price of approximately $5,000 thousand. Certain investors were also granted warrants to acquire 2,262,443 of ordinary shares at an exercise price of $20.87 per share.

Additionally, during 2019, Nanox PLC entered into several agreements with certain third-party investors, pursuant to which it raised an aggregate amount of $4,038 thousand, net of issuance costs, at a purchase price of $2.21 per share.

Ordinary Share issuances after the APA

On December 31, 2019, the Company issued 312,500 ordinary shares to a third-party investor for an aggregate purchase price of approximately $5 million.

During the year 2020, the Company issued an aggregate of 4,624,500 ordinary shares to the certain investors, at a price per share of $16.00, for an aggregate purchase price of approximately $74 million (the net proceeds were approximately $71 million after deducting issuance costs).

In August 2020, the Company completed an initial public offering (“IPO”) on the Nasdaq Global Market (the “Nasdaq”), in which it issued 9,178,744 ordinary shares at a price per share of $18. During August 2020, the underwriters exercised their over-allotment option and purchased an additional 1,376,812 ordinary shares at the same price per share. The proceeds received from the IPO were $190 million (the net proceeds were approximately $169 million after deducting underwriting commissions and other offering expenses).

Settlement of Related Party Liability

Pursuant to the Asset Purchase Agreement between Nanox IL and Nanox PLC, as more fully described in the Company’s annual financial statements, in January 2020, the Company issued 1,109,245 ordinary shares to Nanox PLC with a purchase price of $12.00 per share, which reflected a discount of 25% from the price of the last financing round of the Company. As a result, the related party liability was settled into shareholders’ equity.

Share based compensation

On September 3, 2019, the Company’s Board resolved to adopt an equity incentive plan (the “Plan”). Based on such Plan, each option will be exercisable for one ordinary share of the Company and will become exercisable at such terms and during such periods, as the Board shall determine. Pursuant to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value of the Company are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company’s employees, directors and consultants. As of December 31, 2020, 2,978,247 ordinary shares reserved for the equity incentive plan.

The Board also approved the Plan for the purpose of selecting the capital gains tax track, under Section 102 of the Israeli Income Tax Ordinance, for options granted to the Company’s Israeli employees.

Share-based compensation to non-employees

The following table summarizes share-based awards to non-employees for the years ended December 31, 2020 and December 31, 2019:

	Year ended December 31,					Year ended December 31,
	2020					2019
	Number of			Weighted		Number of			Weighted
	share-based			average		share-based			average
	payment			exercise		payment			exercise
	awards			price		awards			price
Outstanding at beginning of year		3,410,406		$	1.89		1,592,874		$	1.32
Changes during the year:
Granted		1,327,957			13.70		2,271,698		$	2.77
Exercised		*(1,267,012	)		8.94		(454,166	)	$	0.3
Forfeited		-			-		-			-
Expired		-			-		-			-
Cancelled		(98,725	)		1.92		-			-
Outstanding at end of year		3,372,626			5.27		3,410,406		$	1.89
Exercisable at end of year		2,191,042			5.67		1,830,809		$	3.79

*	Out of which 1,027,151 awards were exercised on a cashless basis.

The fair value of each granted award is estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used for the years ended December 31, 2020 and 2019 are as follows:

	2020		2019
Dividend yield		0		0
Expected volatility		57.34%-44.40%		41.11% - 50.59%
Risk-free interest rate		0.27%-1.61%		1.55%-1.76%
Contractual term (years)		5-10		0.50 – 10.00

The expected volatility is based on the historical volatility of comparable companies.

The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the awards granted in dollar terms.

The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life).

The following table summarizes information concerning outstanding and exercisable awards as of December 31, 2020 and 2019:

December 31, 2020
Awards outstanding						Awards exercisable
		Number of		Weighted		Number of		Weighted
		awards		average		award		average
		outstanding		remaining		exercisable		remaining
Exercise		at end of		contractual		at end of		contractual
price		year		life (years)		year		life (years)
$	0.01		186,815		0.33		186,815		0.33
$	1.92		269,714		1.18		269,714		1.18
$	2.21		2,191,349		6.22		1,188,914		6.22
$	16.00		444,748		8.89		283,933		8.89
$	18.00		260,000		3.86		260,000		3.86
$	30.93		20,000		9.81		1,666		9.81

December 31, 2019
Awards outstanding						Awards exercisable
		Number of		Weighted		Number of		Weighted
		awards		average		awards		average
		outstanding		remaining		exercisable		remaining
Exercise		at end of		contractual		at end of		contractual
price		year		life (years)		year		Life (years)
$	0.01		186,815		1.33		186,815		1.33
$	1.92		472,606		1.81		472,606		1.81
$	2.21		2,727,028		5.27		1,163,402		5.27
$	20.87		23,957		5.69		7,986		5.69

Share-based compensation to employees, officers and directors

During 2020, the Company granted to certain employees, officers and directors awards to purchase 730,734 of the Company’s ordinary shares for an average exercise price of $13.53.

	Year ended December 31,					Year ended December 31,
	2020					2019
		Number of			Weighted		Number of		Weighted
		share-based			average		share-based		average
		payment awards			exercise price		payment awards		exercise price
Outstanding at beginning of year		1,667,267		$	2.21		1,667,267	$	2.21
Changes during the year:
Granted		730,734		$	13.53		-		-
Exercised		-			-		-		-
Forfeited		-			-		-		-
Expired		-			-		-		-
Cancelled		(16,876	)	$	2.21		-		-
Outstanding at end of year		2,381,125		$	4.14		1,667,267		2.21
Exercisable at end of year		1,061,778		$	2.80		450,557		2.21

The fair value of each granted award is estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used as of December 31, 2020 and 2019 are as follows:

	2020		2019
Dividend yield		0		0
Expected volatility		45.11%-55.97%		45.11%-55.97%
Risk-free interest rate		0.23%-1.61%		0.23%-1.61%
Contractual term (years)		10		10

The expected volatility is based on the historical volatility of comparable companies.

The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the awards granted in dollar terms.

The following table summarizes information concerning outstanding and exercisable awards as of December 31, 2020 and 2019:

December 31, 2020

Awards outstanding

Awards exercisable

Number of

Weighted

Number of

Weighted

awards

average

awards

average

outstanding

remaining

exercisable

remaining

Exercise

at end of

contractual

at end of

contractual

price

year

life (years)

year

life (years)

$2.21

1,995,625

9.05

1,019,695

9.05

$16.00

205,000

9.62

37,917

9.62

$26.56-$59.20

180,500

9.93

4,167

9.93

December 31, 2019

Awards outstanding

Awards exercisable

Number of

Weighted

Number of

Weighted

awards

average

awards

average

outstanding

remaining

exercisable

remaining

Exercise

at end of

contractual

at end of

contractual

price

year

life (years)

year

life (years)

$2.21

1,667,267

9.90

450,557

9.90

Share-based compensation expenses

	Year Ended December 31,
	2020		2019		2018
	(U.S. dollars in thousands)
Research and development		3,384		661		-
Marketing (*)		9,252		617		-
General and administrative		12,145		14,967		115
		24,781		16,245		115

(*)

On October 26, 2020, the Company entered into an amendment to a business development agreement (“the Agreement”) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company’s systems and the issuance of warrants.

Income Tax

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

INCOME TAX

NOTE 9 -

INCOME TAX:

Basis of taxation

Current tax is calculated with reference to the profit of the Company and its subsidiary in their respective countries of operation. Set out below are details in respect of the significant jurisdictions where the Company and its subsidiary operates and the factors that influenced the current and deferred taxation in those jurisdictions:

Israel

The Company is taxed under the laws of the State of Israel at a corporate tax rate of 23%. In 2020, the Company was at a loss position and therefore had no corporate tax liability.

Korea

Nanox Korea is subject to a Corporate income tax with accordance with the Korean tax law. The tax rate ranges between 10% to 25%, depending on the companies’ taxable income. In Addition, Nanox Korea is subject to a Local income tax of 10%. In 2020, Nanox Korea was at a loss position and therefore had no corporate tax liability.

Japan

Nanox Inc. is subject to national corporate income tax, and enterprise tax, which, in the aggregate resulted in effective tax rate of approximately 33.59% for the year ended December 31, 2020.

Under Japanese tax law and regulations, every company is required to submit an annual tax return to tax authorities. The statute of limitations to request a correction of prior year tax liabilities is five years from when the original tax return was filed. After filling of tax return, the tax authorities may conduct tax inspections on an irregular basis.

Tax assessments

Nanox IL , Nanox Korea and Nanox Inc. have not been assessed since inception.

Deferred tax assets

Nanox IL’s deferred tax asset as of December 31, 2020 was related to tax losses accumulated since September 3, 2019 and carryforward.

A full valuation allowance was created against deferred tax assets arisen from the carryforward tax losses, since the realization of any future benefit from the carryforward tax losses cannot be sufficiently assured as of December 31, 2020.

The reconciling item between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits.

Change in valuation allowance for the year ended December 31, 2020 was $3,262 thousand.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Related Parties - Transactions and Balances

12 Months Ended

Dec. 31, 2020

NOTE 10 - RELATED PARTIES - TRANSACTIONS AND BALANCES:

Balances with related parties:

	December 31,
	2020		2019
	(U.S. Dollars in thousands)
Related party accrued liability		-		72
Related party liability, refer to note 6		-		17,748

Related parties transactions:

	Year ended December 31,
	2020			2019		2018
	(U.S. Dollars in thousands)
Research and development – see c and d below		355			154		542
General and administrative – See c, e and f below		(167	)		5,824		892

Six-Eye Interactive agreements for services

On June 1 2015, Nanox PLC entered into a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company’s CEO and one of major shareholders, pursuant to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee to Nanox PLC. On May 1, 2017, Nanox PLC entered into a services agreement with Six-Eye for the supply of ongoing services, which include research and development services, general and financial management (including accountancy), office management services and operational and supply services. According to the agreement between the parties, Nanox PLC reimburses Six-Eye for its actual direct expenses plus a 12% surplus charge. The agreements were terminated in September 2019. During the years ended December 31 2019 and 2018 the total expenses to Six-Eye were $679 thousand and $1,434 thousand, respectively. In addition to the services provided by Six-Eye during 2019, Six-Eye also paid directly to third-party consultants and suppliers on behalf of the Company in the amount of approximately $1,015 thousand prior to the completion of the Company’s equity financing.

SixAI Ltd Service agreement

On April 16,2020, the Company entered into an agreement with SixAI Ltd. (hereinafter-“SixAI”) a company controlled by Ran Poliakine, the Company’s CEO for certain software development and mechanical engineering services. The service agreement is effective as of March 1, 2020 and has been extended by mutual agreement of the parties to March 31, 2021. During the year ended December 31, 2020, the Company recorded an expense of $355 thousand. Mr. Poliakine currently serves as a member of the board of directors of SixAI and Mr. Poliakine is a significant shareholder of SixAI.

Illumigyn Ltd.

Illumigyn Ltd (hereinafter – “Illumigyn”) is a company in which Ran Poliakine, the Company’s CEO, is a significant shareholder primarily through indirect holdings. Since November 1 2019, Illumigyn sub-leased in transaction approximately 1,800 square feet of private office space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel. Illumigyn pays approximately $12 thousand per month. During the year ended December 31, 2020, the Company received approximately $163 thousand in relation to the sub lease.

Wellsese Technologies Ltd.

Wellsense Technologies Ltd (hereinafter – “Wellsense”) is a company in which Ran Poliakine, the Company’s CEO, and Richard Stone, a member of the Company’s board of directors, are shareholders. Since February 2020, Wellsense has sub-leased private office space, including access to shared public spaces, from the Company in Neve Ilan, Israel. Wellsense pays approximately $7.0 thousand per month. During the year ended December 31, 2020, the Company received $59 thousand, in relation to the sub lease.

Pursuant to the Asset Purchase Agreement between Nanox IL and Nanox PLC, as of December 31, 2020, the Company has settled the related party liability balance of $192 thousand to Nanox Japan and Nanox PLC, mainly for Fixed Assets which were transferred to the Company as part of the APA.

Loss Per Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

LOSS PER SHARE

NOTE 11 - LOSS PER SHARE:

Basic

Basic loss per share is calculated by dividing the loss attributable to the Company’s owners by the weighted average number of ordinary shares in issue.

	Year ended December 31,
	2020			2019			2018
Net loss attributable to Company’s owners	$	(43,815	)	$	(22,563	)		(1,909	)

The weighted average of the number of ordinary shares (in thousands)		35,654			25,181			20,793
Basic and diluted loss per share	$	(1.23	)	$	(0.90	)		(0.09	)

For the calculation of loss per share, the Company used the net loss attributable to Company’s owners divided by the weighted average number of the Company’s ordinary shares for the years ended December 31, 2020, 2019 and 2018.

Diluted

As of December 31, 2020 and 2019 the Company had 7,846,290 and 9,203,124 investor warrants and employees and non-employees option awards, respectively. These warrants and awards were not taken into account when calculating diluted loss per share since their effect is anti-dilutive.

Subsequent Events

12 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 12 - SUBSEQUENT EVENTS:

During 2021, the Company granted a total of 338,929 awards with an average exercise price of $48.59 per share to employees.

In February 2021 the Company completed a secondary offering of 3,091,635 ordinary shares by certain non-director, non-officer selling pre-IPO shareholders. An additional 845,044 shares were locked up for an additional period as part of the agreed terms. The Company cooperated with the offering lead underwriter while each participating shareholder paid the underwriters fees and the Company covered the legal, accounting, administrative and regulatory fees which totaled approximately $818 thousand. The Company received no proceeds from the described above public secondary offering.

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Use of estimates in the preparation of financial statements

a.	Use of estimates in the preparation of financial statements

Functional currency

b.	Functional currency

Cash and cash equivalents

c.	Cash and cash equivalents

Restricted Cash

d.	Restricted Cash

Property and equipment, net

e.	Property and equipment, net

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives:

	%
Computers and electronic equipment	10-33
Office furniture and lab equipment	6-20
Machines	10-20
Leasehold Improvement		10
Land		N/A

The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.

Impairment of long-lived assets

f.	Impairment of long-lived assets

As of December 31, 2020, 2019 and 2018, the Company did not recognize an impairment loss on its long-lived assets.

Severance pay

g.	Severance pay

In 2020, all of the Company’s employees in Israel are subject to Section 14.

Legal and other contingencies

h.	Legal and other contingencies

Research and development expenses

i.	Research and development expenses

Research and development expenses are charged to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.

Income tax

j.	Income tax

Concentration of Credit Risks

k.	Share-based compensation

ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing model as part of such estimation.

Loss per share

l.	Loss per share

The Company did not take into account any dilutive instruments, such as investor warrants and share-based payments, since their effect, on a fully diluted basis, is anti-dilutive.

Fair value measurement

m.	Fair value measurement

	Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

	Level 2:	Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

	Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

n.	Concentration of Credit Risks

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash.

Offering Costs

o.	Offering Costs

Leases

p.	Leases

Newly issued and recently adopted accounting pronouncements

q.	Newly issued and recently adopted accounting pronouncements:

Accounting Pronouncements Adopted in Current year

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of property and equipment

	%
Computers and electronic equipment	10-33
Office furniture and lab equipment	6-20
Machines	10-20
Leasehold Improvement		10
Land		N/A

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	December 31,
	2020			2019
	(U.S. Dollars in thousands)

Office furniture and lab equipment		820			325
Computers and electronic equipment		151			39
Machinery		1,762			-
Leasehold improvement		16			-
Land – See b below		6,297			-
Prepayments on account of production line in construction - See b below		5,318			-
		14,364			364
Less: accumulated depreciation		(344	)		(136	)
Total property and equipment, net		14,020			228

Cash, Cash Equivalents and Restricted Cash (Tables)

12 Months Ended

Dec. 31, 2020

Cash Equivalents And Restricted Cash [Abstract]

Schedule of reconciliation of cash, cash equivalents and restricted cash

	December 31,
	2020		2019
	(U.S. Dollars in thousands)
Cash and cash equivalents		213,468		8,072
Restricted bank deposit		316		145
Total cash, cash equivalents and restricted cash shown in the statement of cash flows		213,784		8,217

Leases (Tables)

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Schedule of the compnay's total lease costs

	Year ended December 31,		Year ended December 31,
	2020		2019
	(U.S. Dollars in thousands)		(U.S. Dollars In thousands)
Operating lease cost:
Fixed payments		276		25
Short-term lease cost		65		112
Total operating lease cost		341		137

Schedule of supplemental cash flow information related to operating leases

	Year ended December 31,		Year ended December 31,
	2020		2019
	(U.S. Dollars in thousands)		(U.S. Dollars in thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		169		25

Right-of-use assets obtained in exchange for lease obligations (non-cash):
Operating leases		1,085		548

Schedule of supplemental balance sheet information

	December 31,			December 31,
	2020			2019
	(U.S. Dollars in thousands)			(U.S. Dollars in thousands)
Operating leases:
Operating lease right-of-use assets		1,359			526

Current maturities of operating leases		519			140
Non-current operating leases		923			386
Total operating lease liabilities		1,442			526

		December 31,			December 31,
		2020			2019
Weighted average remaining lease term
Operating leases		2.67			3.96

Weighted average discount rate
Operating leases		5.83	%		5.6	%

Schedule of maturities of operating lease liabilities

	December 31,
	2020
	(U.S. Dollars in thousands)

2020		-
2021		588
2022		588
2023		382
2024 and thereafter		-
Total operating lease payments		1,558
Less: imputed interest		116
Present value of lease liabilities		1,442

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2020

Shareholders' Equity (Tables) [Line Items]

Schedule of share-based payments to non-employees

	Year ended December 31,					Year ended December 31,
	2020					2019
	Number of			Weighted		Number of			Weighted
	share-based			average		share-based			average
	payment			exercise		payment			exercise
	awards			price		awards			price
Outstanding at beginning of year		3,410,406		$	1.89		1,592,874		$	1.32
Changes during the year:
Granted		1,327,957			13.70		2,271,698		$	2.77
Exercised		*(1,267,012	)		8.94		(454,166	)	$	0.3
Forfeited		-			-		-			-
Expired		-			-		-			-
Cancelled		(98,725	)		1.92		-			-
Outstanding at end of year		3,372,626			5.27		3,410,406		$	1.89
Exercisable at end of year		2,191,042			5.67		1,830,809		$	3.79

Schedule of Black-Scholes option-pricing model

	2020		2019
Dividend yield		0		0
Expected volatility		57.34%-44.40%		41.11% - 50.59%
Risk-free interest rate		0.27%-1.61%		1.55%-1.76%
Contractual term (years)		5-10		0.50 – 10.00

Schedule of information concerning outstanding and exercisable awards

December 31, 2020
Awards outstanding						Awards exercisable
		Number of		Weighted		Number of		Weighted
		awards		average		award		average
		outstanding		remaining		exercisable		remaining
Exercise		at end of		contractual		at end of		contractual
price		year		life (years)		year		life (years)
$	0.01		186,815		0.33		186,815		0.33
$	1.92		269,714		1.18		269,714		1.18
$	2.21		2,191,349		6.22		1,188,914		6.22
$	16.00		444,748		8.89		283,933		8.89
$	18.00		260,000		3.86		260,000		3.86
$	30.93		20,000		9.81		1,666		9.81

December 31, 2019
Awards outstanding						Awards exercisable
		Number of		Weighted		Number of		Weighted
		awards		average		awards		average
		outstanding		remaining		exercisable		remaining
Exercise		at end of		contractual		at end of		contractual
price		year		life (years)		year		Life (years)
$	0.01		186,815		1.33		186,815		1.33
$	1.92		472,606		1.81		472,606		1.81
$	2.21		2,727,028		5.27		1,163,402		5.27
$	20.87		23,957		5.69		7,986		5.69

Schedule of share-based compensation

	Year Ended December 31,
	2020		2019		2018
	(U.S. dollars in thousands)
Research and development		3,384		661		-
Marketing (*)		9,252		617		-
General and administrative		12,145		14,967		115
		24,781		16,245		115

Employees, Officers and Directors [Member]

Shareholders' Equity (Tables) [Line Items]

Schedule of Black-Scholes option-pricing model

	2020		2019
Dividend yield		0		0
Expected volatility		45.11%-55.97%		45.11%-55.97%
Risk-free interest rate		0.23%-1.61%		0.23%-1.61%
Contractual term (years)		10		10

Schedule of information concerning outstanding and exercisable awards

December 31, 2020

Awards outstanding

Awards exercisable

Number of

Weighted

Number of

Weighted

awards

average

awards

average

outstanding

remaining

exercisable

remaining

Exercise

at end of

contractual

at end of

contractual

price

year

life (years)

year

life (years)

$2.21

1,995,625

9.05

1,019,695

9.05

$16.00

205,000

9.62

37,917

9.62

$26.56-$59.20

180,500

9.93

4,167

9.93

December 31, 2019

Awards outstanding

Awards exercisable

Number of

Weighted

Number of

Weighted

awards

average

awards

average

outstanding

remaining

exercisable

remaining

Exercise

at end of

contractual

at end of

contractual

price

year

life (years)

year

life (years)

$2.21

1,667,267

9.90

450,557

9.90

Schedule of shared - based payments to employees

	Year ended December 31,					Year ended December 31,
	2020					2019
		Number of			Weighted		Number of		Weighted
		share-based			average		share-based		average
		payment awards			exercise price		payment awards		exercise price
Outstanding at beginning of year		1,667,267		$	2.21		1,667,267	$	2.21
Changes during the year:
Granted		730,734		$	13.53		-		-
Exercised		-			-		-		-
Forfeited		-			-		-		-
Expired		-			-		-		-
Cancelled		(16,876	)	$	2.21		-		-
Outstanding at end of year		2,381,125		$	4.14		1,667,267		2.21
Exercisable at end of year		1,061,778		$	2.80		450,557		2.21

Related Parties - Transactions and Balances (Tables)

12 Months Ended

Dec. 31, 2020

Schedule of balances with related parties

	December 31,
	2020		2019
	(U.S. Dollars in thousands)
Related party accrued liability		-		72
Related party liability, refer to note 6		-		17,748

	Year ended December 31,
	2020			2019		2018
	(U.S. Dollars in thousands)
Research and development – see c and d below		355			154		542
General and administrative – See c, e and f below		(167	)		5,824		892

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule of basic loss per share is calculated by dividing the loss attributable to the company’s owners

	Year ended December 31,
	2020			2019			2018
Net loss attributable to Company’s owners	$	(43,815	)	$	(22,563	)		(1,909	)

The weighted average of the number of ordinary shares (in thousands)		35,654			25,181			20,793
Basic and diluted loss per share	$	(1.23	)	$	(0.90	)		(0.09	)

General (Details) - USD ($)	1 Months Ended			12 Months Ended
General (Details) - USD ($)	Aug. 31, 2020	Aug. 31, 2020	Nov. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
General (Details) [Line Items]
Ordinary shares, value				$ 169,167,000
Initial public offering net proceeds				$ 169,348,000
Acquired assets, description				Nanox IL shall pay Nanox PLC $6.127 million as consideration for the purchase of the Acquired Assets, which reflects the fair value of the Acquired Assets (excluding cash) plus the cash balance as of the date of the APA, less $200 thousand. The purchase price shall be due and payable upon the closing of one of the following events: (a) an M&A event of Nanox IL, (b) an IPO of Nanox IL, or (c) a qualified equity financing of Nanox IL at a minimum company pre-money valuation of $100 million, with proceeds totaling at least $30 million.
Cash consideration, description			Nanox PLC transferred to Nanox IL an amount of $7.2 million, which reflects the cash consideration under the APA. The total consideration of the purchase of the Acquired Assets is $13.3 million. The outstanding balance of $17.8 million reflects the related party liability of the expected future payment using the Company’s shares, refer to note 6.
IPO [Member]
General (Details) [Line Items]
Ordinary shares, issued (in Shares)		9,178,744
Ordinary shares, value		$ 18
Initial public offering including the options granted to underwriters proceeds		$ 190,000,000
IPO [Member] \| Nasdaq [Member]
General (Details) [Line Items]
Initial public offering net proceeds	$ 169,000,000
Over-Allotment Option [Member]
General (Details) [Line Items]
Ordinary shares, issued (in Shares)		1,376,812

Significant Accounting Policies (Details) - Schedule of property and equipment	12 Months Ended
	Dec. 31, 2020
Computers and electronic equipment [Member]
Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment, percentage	10-33
Office furniture and lab equipment [Member]
Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment, percentage	6-20
Machines [Member]
Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment, percentage	10-20
Leasehold Improvement [Member]
Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment, percentage	10
Land [Member]
Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]
Property and equipment, percentage	N/A

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation	$ 208	$ 53	$ 35
Purchase of land	$ 6,200

Property and Equipment, Net (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 14,364	$ 364
Less: accumulated depreciation	(344)	(136)
Total property and equipment, net	14,020	228
Office furniture and lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	820	325
Computers and electronic equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	151	39
Machinery [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	1,762
Leasehold improvement [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	16
Land – See b below [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	6,297
Prepayments on account of production line in construction - See b below [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 5,318

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of reconciliation of cash, cash equivalents and restricted cash [Abstract]
Cash and cash equivalents	$ 213,468	$ 8,072
Restricted bank deposit	316	145
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 213,784	$ 8,217	$ 5	$ 65

Leases (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
Leases (Details) - USD ($) $ in Thousands	Nov. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Disclosure Text Block [Abstract]
Rent payment agreement, description	During November 2020, following the increase of the Company’s employees, the Company signed an additional lease agreement, for a leasing of another office complex through June 30, 2023.	During June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023.	This agreement is through December 31, 2021 with an option by the Company to extend the period for an additional 24 months.
Rent expenses	$ 12	$ 15	$ 13
Vehicles lease, description	the Company engaged with car lease company, for leasing of 6 vehicles. This agreement is effective through June 30, 2023
Vehicle lease expense	$6.5

Leases (Details) - Schedule of company's total lease costs - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating lease cost:
Fixed payments	$ 276	$ 25
Short-term lease cost	65	112
Total operating lease cost	$ 341	$ 137

Leases (Details) - Schedule of supplemental cash flow information related to operating leases - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 169	$ 25
Right-of-use assets obtained in exchange for lease obligations (non-cash):
Operating leases	$ 1,085	$ 548

Leases (Details) - Schedule of supplemental balance sheet information - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Operating leases:
Operating lease right-of-use assets	$ 1,359	$ 526
Current maturities of operating leases	519	140
Non-current operating leases	923	386
Total operating lease liabilities	$ 1,442	$ 526
Weighted average remaining lease term
Operating leases	2 years 244 days	3 years 350 days
Weighted average discount rate
Operating leases	5.83%	5.60%

Leases (Details) - Schedule of maturities of operating lease liabilities - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of maturities of operating lease liabilities [Abstract]
2020
2021	588
2022	588
2023	382
2024 and thereafter
Total operating lease payments	1,558
Less: imputed interest	116
Present value of lease liabilities	$ 1,442	$ 526

Related Party Liability (Details) - USD ($) $ in Millions	1 Months Ended
Related Party Liability (Details) - USD ($) $ in Millions	Jan. 31, 2020	Dec. 31, 2019
Related Party Liability [Abstract]
Related party liability		$ 17.8
Purchase agreement, description	subject to entering into a share purchase agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Nanox IL’s Board approved the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled into equity.

Shareholders' Equity (Details)	1 Months Ended				12 Months Ended
Shareholders' Equity (Details)	Oct. 26, 2020	Aug. 31, 2020 USD ($) $ / shares shares	Jan. 31, 2020 $ / shares shares	Jun. 17, 2019 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares	Dec. 31, 2018 USD ($) $ / shares	Sep. 03, 2019 ₪ / shares shares
Shareholders' Equity (Details) [Line Items]
Aggregate amount (in Dollars) \| $						$ 312,500	$ 3,684,000
Purchase price (in Dollars per share) \| $ / shares			$ 12.00	$ 20.87	$ 16.00	$ 2,210	$ 2.21
Ordinary shares			1,109,245	2,262,443	4,624,500
Aggregate purchase price (in Dollars) \| $				$ 5,000,000		$ 5,000,000
Aggregate purchase price (in Dollars) \| $					$ 74,000,000
Net proceeds (in Dollars) \| $					71,000,000
Net proceeds from IPO (in Dollars) \| $					$ 169,348,000
Percentage of discount price			25.00%
Ordinary shares reserved under the ESOP								8,041,936
Price per share (in New Shekels per share) \| ₪ / shares								₪ 0.01
Number of exercised shares					1,027,151
Description of share-based compensation expenses	the Company entered into an amendment to a business development agreement (“the Agreement”) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company’s systems and the issuance of warrants.
Nanox PLC [Member]
Shareholders' Equity (Details) [Line Items]
Aggregate amount (in Dollars) \| $						$ 4,038,000
IPO [Member]
Shareholders' Equity (Details) [Line Items]
Purchase price (in Dollars per share) \| $ / shares		$ 18
Ordinary shares		9,178,744
Aggregate purchase price (in Dollars) \| $		$ 190,000,000
Stock Issued During Period, Shares, New Issues		9,178,744
Over-Allotment Option [Member]
Shareholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		1,376,812
Equity Incentive Plan [Member]
Shareholders' Equity (Details) [Line Items]
Ordinary shares					2,978,247
Warrants [Member]
Shareholders' Equity (Details) [Line Items]
Ordinary shares				2,262,443
Employees, Officers and Directors [Member]
Shareholders' Equity (Details) [Line Items]
Ordinary shares					730,734
Exercise price per share (in Dollars per share) \| $ / shares					$ 13.53

Shareholders' Equity (Details) - Schedule of share-based payments to non-employees - $ / shares

12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Schedule of share-based payments to non-employees [Abstract]

Number of share-based payment awards, Outstanding at beginning balance

3,410,406

1,592,874

Weighted average exercise price, Outstanding at beginning balance

$ 1.89

$ 1.32

Number of share-based payment awards, Granted

1,327,957

2,271,698

Weighted average exercise price, Granted

$ 13.70

$ 2.77

Number of share-based payment awards, Exercised

(1,267,012)

^[1]

(454,166)

Weighted average exercise price, Exercised

$ 8.94

$ 0.3

Number of share-based payment awards, Forfeited

Weighted average exercise price, Forfeited

Number of share-based payment awards, Expired

Weighted average exercise price, Expired

Number of share-based payment awards, Cancelled

(98,725)

Weighted average exercise price. Cancelled

$ 1.92

Number of share-based payment awards, Outstanding at ending balance

3,372,626

3,410,406

Weighted average exercise price, Outstanding at ending balance

$ 5.27

$ 1.89

Number of share-based payment awards, Exercisable

2,191,042

1,830,809

Weighted average exercise price, Exercisable

$ 5.67

$ 3.79

[1]	Out of which 1,027,151 awards were exercised on a cashless basis.

Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]
Expected volatility	57.34%	41.11%
Risk-free interest rate	0.27%	1.55%
Contractual term (years)	5 years	6 months
Maximum [Member]
Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]
Expected volatility	44.40%	50.59%
Risk-free interest rate	1.61%	1.76%
Contractual term (years)	10 years	10 years

Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
0.01 Exercise Price [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	186,815	186,815
Awards outstanding, Weighted average remaining contractual life (years)	120 days	1 year 120 days
Awards exercisable, Number of awards outstanding balance	186,815	186,815
Awards exercisable, Weighted average remaining contractual life (years)	120 days	1 year 120 days
1.92 Exercise Price [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	269,714	472,606
Awards outstanding, Weighted average remaining contractual life (years)	1 year 65 days	1 year 295 days
Awards exercisable, Number of awards outstanding balance	269,714	472,606
Awards exercisable, Weighted average remaining contractual life (years)	1 year 65 days	1 year 295 days
2.21 Exercise Price [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	2,191,349	2,727,028
Awards outstanding, Weighted average remaining contractual life (years)	6 years 80 days	5 years 98 days
Awards exercisable, Number of awards outstanding balance	1,188,914	1,163,402
Awards exercisable, Weighted average remaining contractual life (years)	6 years 80 days	5 years 98 days
16.00 Exercise Price [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	444,748
Awards outstanding, Weighted average remaining contractual life (years)	8 years 324 days
Awards exercisable, Number of awards outstanding balance	283,933
Awards exercisable, Weighted average remaining contractual life (years)	8 years 324 days
18.00 Exercise Price [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	260,000
Awards outstanding, Weighted average remaining contractual life (years)	3 years 313 days
Awards exercisable, Number of awards outstanding balance	260,000
Awards exercisable, Weighted average remaining contractual life (years)	3 years 313 days
30.93 Exercise Price [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	20,000
Awards outstanding, Weighted average remaining contractual life (years)	9 years 295 days
Awards exercisable, Number of awards outstanding balance	1,666
Awards exercisable, Weighted average remaining contractual life (years)	9 years 295 days
20.87 Exercise Price [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance		23,957
Awards outstanding, Weighted average remaining contractual life (years)		5 years 251 days
Awards exercisable, Number of awards outstanding balance		7,986
Awards exercisable, Weighted average remaining contractual life (years)		5 years 251 days

Shareholders' Equity (Details) - Schedule of shared - based payments to employees - Employee Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Shareholders' Equity (Details) - Schedule of shared - based payments to employees [Line Items]
Number of share-based payment awards, Outstanding at beginning balance	1,667,267	1,667,267
Weighted average exercise price, Outstanding at beginning	$ 2.21	$ 2.21
Changes during the year:
Number of share-based payment awards, Granted	730,734
Weighted average exercise price, Granted	$ 13.53
Number of share-based payment awards, Exercised
Weighted average exercise price Exercised
Number of share-based payment awards, Forfeited
Weighted average exercise price, Forfeited
Number of share-based payment awards, Expired
Weighted average exercise price, Expired
Number of share-based payment awards, Cancelled	(16,876)
Weighted average exercise price, Cancelled	$ 2.21
Number of share-based payment awards, Outstanding at ending balance	2,381,125	1,667,267
Weighted average exercise price, Outstanding at ending balance	$ 4.14	$ 2.21
Number of share-based payment awards, Exercisable	1,061,778	450,557
Weighted average exercise price, Exercisable	$ 2.80	$ 2.21

Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model - Employee Stock [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model [Line Items]
Dividend yield	0.00%	0.00%
Contractual term (years)	10 years	10 years
Minimum [Member]
Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model [Line Items]
Expected volatility	45.11%	45.11%
Risk-free interest rate	0.23%	0.23%
Maximum [Member]
Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model [Line Items]
Expected volatility	55.97%	55.97%
Risk-free interest rate	1.61%	1.61%

Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards - Employees, Officers and Directors [Member] - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Exercise Prices One [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	1,995,625	1,667,267
Awards outstanding, Weighted average remaining contractual life (years)	9 years 18 days	9 years 328 days
Awards exercisable, Number of awards outstanding balance	1,019,695	450,557
Awards exercisable, Weighted average remaining contractual life (years)	9 years 18 days	9 years 328 days
Exercise Prices Two [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	205,000
Awards outstanding, Weighted average remaining contractual life (years)	9 years 226 days
Awards exercisable, Number of awards outstanding balance	37,917
Awards exercisable, Weighted average remaining contractual life (years)	9 years 226 days
Exercise Prices Three [Member]
Class of Warrant or Right [Line Items]
Awards outstanding, Number of awards outstanding balance	180,500
Awards outstanding, Weighted average remaining contractual life (years)	9 years 339 days
Awards exercisable, Number of awards outstanding balance	4,167
Awards exercisable, Weighted average remaining contractual life (years)	9 years 339 days

Shareholders' Equity (Details) - Schedule of share-based compensation - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Shareholders' Equity (Details) - Schedule of share-based compensation [Line Items]

Research and Development [Member]

$ 24,781

$ 16,245

$ 115

Shareholders' Equity (Details) - Schedule of share-based compensation [Line Items]

Shareholders' Equity (Details) - Schedule of share-based compensation [Line Items]

3,384

661

Marketing [Member]

General and Administrative [Member]

^[1]

9,252

617

Shareholders' Equity (Details) - Schedule of share-based compensation [Line Items]